FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012158392> ?p ?o ?g. }

• W2012158392 endingPage "1156.e3" @default.
• W2012158392 startingPage "1143" @default.
• W2012158392 abstract "ObjectiveThe aim of the present study has been to establish serum-free culture conditions for ex vivo expansion and differentiation of human CD34+ cells into erythroid lineage and to study the chromatin structure, gene expression, and transcription factor recruitment at the α-globin locus in the developing erythron.Materials and MethodsA basal Iscove's modified Dulbecco's medium cell culture medium with 1% bovine serum albumin as a serum replacement and a combination of cytokines and growth factors was used for expansion and differentiation of the CD34+ cells. Expression patterns of the α- and β-like genes at various stages of erythropoiesis was studied by reverse transcriptase quantitative polymerase chain reaction analysis, profile of key erythroid transcription factors was investigated by Western blotting, and the chromatin structure and transcription factor recruitment at the α-globin locus was investigated by chromatin immunoprecipitation quantitative polymerase chain reaction analysis.ResultsHuman CD34+ cells in the serum-free medium undergo near synchronous erythroid differentiation to yield large amount of cells at different differentiation stages. We observe distinct patterns of the histone modifications and transcription factor binding at the α-globin locus during erythroid differentiation of CD34+ cells. Nuclear factor erythroid-derived 2 (NF-E2) was present at upstream activator sites even before addition of erythropoietin (EPO), while bound GATA-1 was only detectable after EPO treatment. After 7 days of EPO treatment, H3K4Me2 modification uniformly increases throughout the α-globin locus. Acetylation at H3K9 and binding of Pol II, NF-E2, and GATA-1 were restricted to certain hypersensitive sites of the enhancer and θ gene, and were conspicuously low at the α-like globin promoters. Rearrangement of the insulator binding factor CTCF took place at and around the α-globin locus as CD34+ cells differentiated into erythroid pathway.ConclusionOur results indicate that remodeling of the upstream elements may be the primary event in activation of α-globin gene expression. Activation of α-globin genes upon EPO treatment involves initial binding of Pol II, downregulation of pre-existing factors like NF-E2, removal of CTCF from the locus, then rebinding of CTCF in an altered pattern, and concurrent or subsequent binding of transcription factors like GATA-1. The aim of the present study has been to establish serum-free culture conditions for ex vivo expansion and differentiation of human CD34+ cells into erythroid lineage and to study the chromatin structure, gene expression, and transcription factor recruitment at the α-globin locus in the developing erythron. A basal Iscove's modified Dulbecco's medium cell culture medium with 1% bovine serum albumin as a serum replacement and a combination of cytokines and growth factors was used for expansion and differentiation of the CD34+ cells. Expression patterns of the α- and β-like genes at various stages of erythropoiesis was studied by reverse transcriptase quantitative polymerase chain reaction analysis, profile of key erythroid transcription factors was investigated by Western blotting, and the chromatin structure and transcription factor recruitment at the α-globin locus was investigated by chromatin immunoprecipitation quantitative polymerase chain reaction analysis. Human CD34+ cells in the serum-free medium undergo near synchronous erythroid differentiation to yield large amount of cells at different differentiation stages. We observe distinct patterns of the histone modifications and transcription factor binding at the α-globin locus during erythroid differentiation of CD34+ cells. Nuclear factor erythroid-derived 2 (NF-E2) was present at upstream activator sites even before addition of erythropoietin (EPO), while bound GATA-1 was only detectable after EPO treatment. After 7 days of EPO treatment, H3K4Me2 modification uniformly increases throughout the α-globin locus. Acetylation at H3K9 and binding of Pol II, NF-E2, and GATA-1 were restricted to certain hypersensitive sites of the enhancer and θ gene, and were conspicuously low at the α-like globin promoters. Rearrangement of the insulator binding factor CTCF took place at and around the α-globin locus as CD34+ cells differentiated into erythroid pathway. Our results indicate that remodeling of the upstream elements may be the primary event in activation of α-globin gene expression. Activation of α-globin genes upon EPO treatment involves initial binding of Pol II, downregulation of pre-existing factors like NF-E2, removal of CTCF from the locus, then rebinding of CTCF in an altered pattern, and concurrent or subsequent binding of transcription factors like GATA-1." @default.
• W2012158392 created "2016-06-24" @default.
• W2012158392 creator A5004477857 @default.
• W2012158392 creator A5016341690 @default.
• W2012158392 creator A5036198914 @default.
• W2012158392 creator A5053908601 @default.
• W2012158392 creator A5065215242 @default.
• W2012158392 date "2009-10-01" @default.
• W2012158392 modified "2023-10-17" @default.
• W2012158392 title "Dynamics of α-globin locus chromatin structure and gene expression during erythroid differentiation of human CD34+ cells in culture" @default.
• W2012158392 cites W125371635 @default.
• W2012158392 cites W1517824096 @default.
• W2012158392 cites W1538978269 @default.
• W2012158392 cites W1575784571 @default.
• W2012158392 cites W1973049010 @default.
• W2012158392 cites W1973342161 @default.
• W2012158392 cites W1987684996 @default.
• W2012158392 cites W1991066015 @default.
• W2012158392 cites W1992490487 @default.
• W2012158392 cites W1998360443 @default.
• W2012158392 cites W2001296891 @default.
• W2012158392 cites W2003406586 @default.
• W2012158392 cites W2005281324 @default.
• W2012158392 cites W2006055982 @default.
• W2012158392 cites W2006463715 @default.
• W2012158392 cites W2022969404 @default.
• W2012158392 cites W2026501344 @default.
• W2012158392 cites W2042745425 @default.
• W2012158392 cites W204316109 @default.
• W2012158392 cites W2043247638 @default.
• W2012158392 cites W2047187117 @default.
• W2012158392 cites W2047981620 @default.
• W2012158392 cites W2056264836 @default.
• W2012158392 cites W2061050681 @default.
• W2012158392 cites W2062254735 @default.
• W2012158392 cites W2072607983 @default.
• W2012158392 cites W2075038282 @default.
• W2012158392 cites W2078547860 @default.
• W2012158392 cites W2080881193 @default.
• W2012158392 cites W2081391072 @default.
• W2012158392 cites W2082915580 @default.
• W2012158392 cites W2083245183 @default.
• W2012158392 cites W2083403694 @default.
• W2012158392 cites W2102960170 @default.
• W2012158392 cites W2108691372 @default.
• W2012158392 cites W2124158780 @default.
• W2012158392 cites W2131382540 @default.
• W2012158392 cites W2133938268 @default.
• W2012158392 cites W2141171810 @default.
• W2012158392 cites W2141340108 @default.
• W2012158392 cites W2155833731 @default.
• W2012158392 cites W2157519897 @default.
• W2012158392 cites W2157835438 @default.
• W2012158392 cites W2158804694 @default.
• W2012158392 cites W2160003307 @default.
• W2012158392 cites W2162912283 @default.
• W2012158392 cites W2165494690 @default.
• W2012158392 cites W2166647372 @default.
• W2012158392 cites W2166862788 @default.
• W2012158392 cites W2168602111 @default.
• W2012158392 cites W226172386 @default.
• W2012158392 cites W2384503513 @default.
• W2012158392 cites W2441117493 @default.
• W2012158392 cites W4240595978 @default.
• W2012158392 cites W4251664538 @default.
• W2012158392 doi "https://doi.org/10.1016/j.exphem.2009.07.001" @default.
• W2012158392 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2997688" @default.
• W2012158392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19607874" @default.
• W2012158392 hasPublicationYear "2009" @default.
• W2012158392 type Work @default.
• W2012158392 sameAs 2012158392 @default.
• W2012158392 citedByCount "24" @default.
• W2012158392 countsByYear W20121583922012 @default.
• W2012158392 countsByYear W20121583922013 @default.
• W2012158392 countsByYear W20121583922014 @default.
• W2012158392 countsByYear W20121583922015 @default.
• W2012158392 countsByYear W20121583922016 @default.
• W2012158392 countsByYear W20121583922017 @default.
• W2012158392 countsByYear W20121583922018 @default.
• W2012158392 countsByYear W20121583922020 @default.
• W2012158392 countsByYear W20121583922021 @default.
• W2012158392 countsByYear W20121583922022 @default.
• W2012158392 crossrefType "journal-article" @default.
• W2012158392 hasAuthorship W2012158392A5004477857 @default.
• W2012158392 hasAuthorship W2012158392A5016341690 @default.
• W2012158392 hasAuthorship W2012158392A5036198914 @default.
• W2012158392 hasAuthorship W2012158392A5053908601 @default.
• W2012158392 hasAuthorship W2012158392A5065215242 @default.
• W2012158392 hasBestOaLocation W20121583921 @default.
• W2012158392 hasConcept C101762097 @default.
• W2012158392 hasConcept C10205521 @default.
• W2012158392 hasConcept C104317684 @default.
• W2012158392 hasConcept C111936080 @default.
• W2012158392 hasConcept C125996951 @default.
• W2012158392 hasConcept C126322002 @default.
• W2012158392 hasConcept C134320426 @default.
• W2012158392 hasConcept C148738053 @default.
• W2012158392 hasConcept C150194340 @default.

• next